Quick Read
-
Envista (NVST) posted Q1 FY26 revenue of $705.5M growing 14.4% year-over-year with adjusted EPS of $0.36 topping estimates by 14.94%, while management reaffirmed full-year guidance of $1.35 to $1.45 and authorized a $300M share buyback through December 31, 2029. Bausch & Lomb (BLCO) reported Q1 FY26 revenue of $1.244B up 9.4% year-over-year and swung to $33M in operating income from a $83M loss, with pharmaceuticals segment MIEBO and XIIDRA growing 33% and 30% respectively, driving management to raise full-year revenue guidance to $5.420B to $5.520B and adjusted EBITDA to $1.010B to $1.060B.
-
Rising personal healthcare spending at $3.741.3B through March 2026 outpacing total consumption growth is making defensive medical device names attractive to retail investors as consumer sentiment languishes at 53.3 in pessimistic territory.
-
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Bausch & Lomb wasn’t one of them. Get them here FREE.
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets. Healthcare keeps that promise. Personal healthcare spending climbed from $3.432 trillion in January 2025 to $3.741 trillion by March 2026, outpacing total consumption while motor vehicles and other discretionary categories softened. Medical device stocks trading below $30 give individual investors an affordable way to ride that resilience.
With that in mind, here are two medical device stocks under $30 that look attractive on fundamentals, guidance and capital-return policy heading into the back half of 2026.
Envista (NYSE: NVST)
Envista (NYSE:NVST) is a dental products holding company whose brands include DEXIS, Kerr, Nobel Biocare, Ormco and Spark clear aligners.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Bausch & Lomb wasn’t one of them. Get them here FREE.
Shares closed at $24.28 on May 12, 2026, up 11.84% year to date and 30.89% over the past year, which keeps the name well inside the sub-$30 bucket. The most recent quarter strengthens the case. Q1 FY26 revenue of $705.5 million grew 14.4% year over year and beat consensus by 3.74%, while adjusted EPS of $0.36 topped the $0.3132 estimate by 14.94%. Adjusted EBITDA rose 25% to $98.9 million, and management reaffirmed full-year adjusted EPS guidance of $1.35 to $1.45.
The bull case is straightforward. Core revenue expanded across every major business, Spark aligners turned profitable in the second half of 2025, and the board authorized a new $300 million share buyback running through December 31, 2029. CEO Paul Keel called the quarter “a good start to 2026” with momentum carrying into the back half. The leadership team also received broad equity awards in February, a signal of internal confidence at recent price levels.
The key risk: free cash flow swung to negative $15.7 million in Q1, and management flagged tariff exposure plus pricing pressure from China’s volume-based procurement program. Those are real headwinds, but they sit against guided adjusted EBITDA growth of 7% to 13%. For investors who want dental exposure with a clear capital-return story, Envista screens well at this price.
Bausch & Lomb (NYSE: BLCO)
Bausch & Lomb (NYSE:BLCO) is an eye health company selling contact lenses, surgical implants and prescription pharmaceuticals across the MIEBO, XIIDRA, LUMIFY and PreserVision brands.
The stock changed hands at $16.03 on May 12, 2026, off 6.15% year to date but up 34.82% over the past year. That pullback looks more like consolidation than rejection. Q1 FY26 revenue reached $1.244 billion, up 9.4% year over year, and the company swung to $33 million in operating income from an $83 million loss a year earlier. Adjusted EPS of $0.05 came in 6.72% below consensus, yet management still raised full-year revenue guidance to $5.420 billion to $5.520 billion and adjusted EBITDA to $1.010 billion to $1.060 billion.
The growth engine is pharmaceuticals. MIEBO grew 33% and XIIDRA grew 30%, lifting the segment 14%. CEO Brent Saunders said the company is “driving sustainable growth and margin expansion”, and H.C. Wainwright carries a Buy rating with a $20 price target. Four independent directors also bought shares at $15.90 on April 30, 2026, a tangible vote of confidence right near the current quote.
The principal risk is structural. Bausch & Lomb is still working through its separation from Bausch Health Companies, carries roughly $97 million in quarterly interest expense and continues to post GAAP losses. Tariff policy could also pressure the international book. For investors comfortable with a leveraged separation story, the eye-care franchise has visible momentum.
Envista and Bausch & Lomb both pair growth with real balance-sheet questions, so position size, time horizon and personal risk tolerance still matter. Read the filings, watch the next quarter and decide what actually fits your portfolio.
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks
This analyst’s 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.
Disclaimer : This story is auto aggregated by a computer programme and has not been created or edited by DOWNTHENEWS. Publisher: finance.yahoo.com
